

Resource Summary Report

Generated by [dkNET](#) on Aug 14, 2026

Somatostatin Receptor 5 antibody [UMB4]

RRID:AB_10859946

Type: Antibody

Proper Citation

Abcam Cat# ab109495, RRID:AB_10859946

Antibody Information

URL: http://antibodyregistry.org/AB_10859946

Proper Citation: Abcam Cat# ab109495, RRID:AB_10859946

Target Antigen: Somatostatin Receptor 5 antibody [UMB4]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Immunohistochemistry - fixed; Immunocytochemistry; Immunohistochemistry; Western Blot; ICC, IHC-P, WB

Antibody Name: Somatostatin Receptor 5 antibody [UMB4]

Description: This monoclonal targets Somatostatin Receptor 5 antibody [UMB4]

Target Organism: rat, mouse, human

Antibody ID: AB_10859946

Vendor: Abcam

Catalog Number: ab109495

Record Creation Time: 20250819T234140+0000

Record Last Update: 20250820T060737+0000

Ratings and Alerts

No rating or validation information has been found for Somatostatin Receptor 5 antibody [UMB4].

No alerts have been found for Somatostatin Receptor 5 antibody [UMB4].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lamback E, et al. (2026) Differential expression of POMC-processing genes in corticotroph tumors. *Endocrine oncology* (Bristol, England), 6(1), e260003.

Itoh H, et al. (2026) GH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly. *Pituitary*, 29(4).

Cosma GM, et al. (2025) Immunohistochemical analysis of filamin a expression in acromegaly and its correlation with tumor characteristics and treatment response. *Scientific reports*, 15(1), 40706.

Mitsui Y, et al. (2024) Growth hormone increase by luteinizing hormone-releasing hormone reflects gonadotroph-related characteristics in acromegaly. *Pituitary*, 27(5), 527.

Campana C, et al. (2024) Digital quantification of somatostatin receptor subtypes 2 and 5 in GH-secreting pituitary tumors. *European journal of endocrinology*.

Gliga MC, et al. (2024) Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin. *International journal of molecular sciences*, 25(16).

Peltola E, et al. (2023) Immunohistochemical somatostatin receptor expression in insulinomas. *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica*, 131(4), 152.

Henriques DG, et al. (2023) miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. *International journal of molecular sciences*, 24(3).

Lutsenko A, et al. (2022) Circulating Plasma MicroRNA in Patients With Active Acromegaly. *The Journal of clinical endocrinology and metabolism*, 107(2), 500.

Faria O, et al. (2022) Characterization of sporadic somatotropinomas with high GIP receptor expression. *Pituitary*, 25(6), 903.

Ilie MD, et al. (2022) Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly-A Prospective Study. The Journal of clinical endocrinology and metabolism, 107(11), 2982.

Amar?? J, et al. (2021) Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects. Cancers, 13(8).